Novel commercially available genomic tests for prostate cancer: A roadmap to understanding their clinical impact

John W. Davis

doi:10.1111/bju.12695

Novel commercially available genomic tests for prostate cancer: A roadmap to understanding their clinical impact

John W. Davis

Urology

Research output: Contribution to journal › Comment/debate › peer-review

19 Scopus citations

Original language	English (US)
Pages (from-to)	320-322
Number of pages	3
Journal	BJU international
Volume	114
Issue number	3
DOIs	https://doi.org/10.1111/bju.12695
State	Published - 2014

ASJC Scopus subject areas

Urology

Access to Document

10.1111/bju.12695

Cite this

@article{0b7154f486b64dd696210197fd406d3c,

title = "Novel commercially available genomic tests for prostate cancer: A roadmap to understanding their clinical impact",

author = "Davis, {John W.}",

year = "2014",

doi = "10.1111/bju.12695",

language = "English (US)",

volume = "114",

pages = "320--322",

journal = "BJU international",

issn = "1464-4096",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Novel commercially available genomic tests for prostate cancer

T2 - A roadmap to understanding their clinical impact

AU - Davis, John W.

PY - 2014

Y1 - 2014

UR - http://www.scopus.com/inward/record.url?scp=84906937446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906937446&partnerID=8YFLogxK

U2 - 10.1111/bju.12695

DO - 10.1111/bju.12695

M3 - Comment/debate

C2 - 25146527

AN - SCOPUS:84906937446

SN - 1464-4096

VL - 114

SP - 320

EP - 322

JO - BJU international

JF - BJU international

IS - 3

ER -

Novel commercially available genomic tests for prostate cancer: A roadmap to understanding their clinical impact

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this